Publications by authors named "Taihei Ono"

Claim this Profile
F
First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
Satoshi Igawa, Tomoya Fukui, Masashi Kasajima, Taihei Ono, Takahiro Ozawa

Invest New Drugs· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with Mutation-Positive Non-Small Cell Lung Cancer.
Satoshi Igawa, Masashi Kasajima, Taihei Ono, Takahiro Ozawa, Mikiko Kakegawa

Cancer Manag Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.
Satoshi Igawa, Taihei Ono, Masashi Kasajima, Seiichiro Kusuhara, Sakiko Otani

Invest New Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi, Yuriko Okuma, Ai Sugimoto

Invest New Drugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer.
Satoshi Igawa, Taihei Ono, Masashi Kasajima, Hideaki Manabe, Tomoya Fukui

Cancer Manag Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of genotype on the efficacy of osimertinib in tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
Satoshi Igawa, Taihei Ono, Masashi Kasajima, Mikiko Ishihara, Yasuhiro Hiyoshi

Cancer Manag Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Taihei Ono, Satoshi Igawa, Takahiro Ozawa, Masashi Kasajima, Mikiko Ishihara

Thorac Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.
Satoshi Igawa, Masayuki Shirasawa, Takahiro Ozawa, Noriko Nishinarita, Yuriko Okuma, Taihei Ono

Thorac Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Satoshi Igawa, Masayuki Shirasawa, Tomoya Fukui, Noriko Nishinarita, Hideyuki Sone, Taihei Ono

Oncology· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis